Literature DB >> 26542505

Soluble receptor for advanced glycation end products and the risk for incident heart failure: The Atherosclerosis Risk in Communities Study.

Mariana Lazo1, Marc K Halushka2, Lu Shen3, Nisa Maruthur4, Casey M Rebholz3, Andreea M Rawlings3, Ron C Hoogeveen5, Tina E Brinkley6, Christie M Ballantyne5, Brad C Astor7, Elizabeth Selvin4.   

Abstract

BACKGROUND: Experimental studies in animals suggest that circulating soluble receptor for advanced glycation end products (sRAGE) decrease oxidative stress, inflammation, and fibrosis. The association between sRAGE and incident heart failure has not been systematically examined in a prospective study.
METHODS: We conducted a prospective analysis of a subsample of 1,086 participants from the Atherosclerosis Risk in Communities Study who attended visit 2 (1990-1992) without a history of coronary heart disease, stroke, or heart failure and with measured plasma sRAGE levels. Incident heart failure was defined as death from heart failure or hospitalization due to heart failure during a median of 20 years of follow-up.
RESULTS: In this sample of a community-based population (mean age 63 years, 60% women, 78% white), there were 126 incident cases of heart failure. Lower levels of sRAGE were significantly associated with an increased risk of heart failure; the adjusted hazard ratios (95% CIs) of heart failure were 1.0 (reference), 1.81 (0.94-3.49), 1.57 (0.80-3.08), and 3.37 (1.75-6.50), for fourth, third, second, and first quartiles, respectively (P for trend = .001). We did not observe significant interactions by diabetes status or by race or obesity status.
CONCLUSIONS: Lower circulating levels of sRAGE are independently associated with the development of heart failure in a community-based population. Our results add to the growing evidence that sRAGE is a valuable predictor of cardiovascular disease.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26542505      PMCID: PMC4638130          DOI: 10.1016/j.ahj.2015.08.008

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  28 in total

1.  Classification of heart failure in the atherosclerosis risk in communities (ARIC) study: a comparison of diagnostic criteria.

Authors:  Wayne D Rosamond; Patricia P Chang; Chris Baggett; Anna Johnson; Alain G Bertoni; Eyal Shahar; Anita Deswal; Gerardo Heiss; Lloyd E Chambless
Journal:  Circ Heart Fail       Date:  2012-01-23       Impact factor: 8.790

Review 2.  Biomarkers in heart failure.

Authors:  Eugene Braunwald
Journal:  N Engl J Med       Date:  2008-05-15       Impact factor: 91.245

3.  Soluble receptor for AGE (RAGE) is a novel independent predictor of all-cause and cardiovascular mortality in type 1 diabetes.

Authors:  M C Thomas; J Söderlund; M Lehto; V-P Mäkinen; J L Moran; M E Cooper; C Forsblom; P-H Groop
Journal:  Diabetologia       Date:  2011-05-24       Impact factor: 10.122

4.  Increased serum high-mobility group box-1 and cleaved receptor for advanced glycation endproducts levels and decreased endogenous secretory receptor for advanced glycation endproducts levels in diabetic and non-diabetic patients with heart failure.

Authors:  Ling Jie Wang; Lin Lu; Feng Ru Zhang; Qiu Jing Chen; Raffaele De Caterina; Wei Feng Shen
Journal:  Eur J Heart Fail       Date:  2011-01-24       Impact factor: 15.534

5.  Relation of soluble receptor for advanced glycation end products to predict mortality in patients with chronic heart failure independently of Seattle Heart Failure Score.

Authors:  Sergio Raposeiras-Roubín; Bruno K Rodiño-Janeiro; Lilian Grigorian-Shamagian; María Moure-González; Ana Seoane-Blanco; Alfonso Varela-Román; Luis Almenar-Bonet; Ezequiel Alvarez; José R González-Juanatey
Journal:  Am J Cardiol       Date:  2011-01-19       Impact factor: 2.778

6.  Advanced glycation end products and their circulating receptors predict cardiovascular disease mortality in older community-dwelling women.

Authors:  Richard D Semba; Luigi Ferrucci; Kai Sun; Justine Beck; Mansi Dalal; Ravi Varadhan; Jeremy Walston; Jack M Guralnik; Linda P Fried
Journal:  Aging Clin Exp Res       Date:  2009-04       Impact factor: 3.636

7.  Factors associated with serum high mobility group box 1 (HMGB1) levels in a general population.

Authors:  Ako Fukami; Hisashi Adachi; Sho-ichi Yamagishi; Takanori Matsui; Shin-ichiro Ueda; Kazuo Nakamura; Mika Enomoto; Maki Otsuka; Shun-ichi Kumagae; Yasuki Nanjo; Eita Kumagai; Eishi Esaki; Kyoko Murayama; Yuji Hirai; Tsutomu Imaizumi
Journal:  Metabolism       Date:  2009-07-17       Impact factor: 8.694

Review 8.  Soluble form of a receptor for advanced glycation end products (sRAGE) as a biomarker.

Authors:  Sho-ichi Yamagishi; Takanori Matsui
Journal:  Front Biosci (Elite Ed)       Date:  2010-06-01

9.  Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 diabetes: an analysis from the CARDS trial.

Authors:  Helen M Colhoun; D John Betteridge; Paul Durrington; Graham Hitman; Andrew Neil; Shona Livingstone; Valentine Charlton-Menys; Weihang Bao; David A Demicco; Gregory M Preston; Harshal Deshmukh; Kathryn Tan; John H Fuller
Journal:  Diabetes       Date:  2011-07-19       Impact factor: 9.461

10.  Association between circulating soluble receptor for advanced glycation end products and atherosclerosis: observations from the Dallas Heart Study.

Authors:  Jason B Lindsey; James A de Lemos; Francesco Cipollone; Colby R Ayers; Anand Rohatgi; David A Morrow; Amit Khera; Darren K McGuire
Journal:  Diabetes Care       Date:  2009-04-14       Impact factor: 19.112

View more
  19 in total

Review 1.  Diabetic cardiomyopathy: a hyperglycaemia- and insulin-resistance-induced heart disease.

Authors:  Guanghong Jia; Adam Whaley-Connell; James R Sowers
Journal:  Diabetologia       Date:  2017-08-03       Impact factor: 10.122

2.  Cross-sectional Analysis of AGE-CML, sRAGE, and esRAGE with Diabetes and Cardiometabolic Risk Factors in a Community-Based Cohort.

Authors:  Stephanie J Loomis; Yuan Chen; David B Sacks; Eric S Christenson; Robert H Christenson; Casey M Rebholz; Elizabeth Selvin
Journal:  Clin Chem       Date:  2017-03-09       Impact factor: 8.327

Review 3.  The use of the soluble receptor for advanced glycation-end products (sRAGE) as a potential biomarker of disease risk and adverse outcomes.

Authors:  Jorge D Erusalimsky
Journal:  Redox Biol       Date:  2021-03-29       Impact factor: 11.799

4.  Follicular fluid soluble receptor for advanced glycation endproducts (sRAGE): a potential protective role in polycystic ovary syndrome.

Authors:  BiJun Wang; MengMeng Hao; QingLing Yang; Jing Li; YiHong Guo
Journal:  J Assist Reprod Genet       Date:  2016-03-24       Impact factor: 3.357

5.  Association between the soluble receptor for advanced glycation end products (sRAGE) and NAFLD in participants in the Atherosclerosis Risk in Communities Study.

Authors:  Marci Laudenslager; Mariana Lazo; Dan Wang; Elizabeth Selvin; Po-Hung Chen; James S Pankow; Jeanne M Clark
Journal:  Dig Liver Dis       Date:  2021-02-24       Impact factor: 5.165

6.  Diagnostic Potential of Evaluation of SDF-1α and sRAGE Levels in Threatened Premature Labor.

Authors:  Rafał Rzepka; Barbara Dołęgowska; Aleksandra Rajewska; Daria Sałata; Marta Budkowska; Sebastian Kwiatkowski; Andrzej Torbé
Journal:  Biomed Res Int       Date:  2016-07-31       Impact factor: 3.411

7.  Increased Levels of sRAGE in Diabetic CKD-G5D Patients: A Potential Protective Mechanism against AGE-Related Upregulation of Fibroblast Growth Factor 23 and Inflammation.

Authors:  Elena Dozio; Valentina Corradi; Elena Vianello; Elisa Scalzotto; Massimo de Cal; Massimiliano Marco Corsi Romanelli; Claudio Ronco
Journal:  Mediators Inflamm       Date:  2017-09-25       Impact factor: 4.711

Review 8.  The Diabetic Cardiomyopathy: The Contributing Pathophysiological Mechanisms.

Authors:  Teresa Salvatore; Pia Clara Pafundi; Raffaele Galiero; Gaetana Albanese; Anna Di Martino; Alfredo Caturano; Erica Vetrano; Luca Rinaldi; Ferdinando Carlo Sasso
Journal:  Front Med (Lausanne)       Date:  2021-06-30

9.  Mouse RAGE Variant 4 Is a Dominant Membrane Receptor that Does Not Shed to Generate Soluble RAGE.

Authors:  Yunqian Peng; Naftali Horwitz; Edward G Lakatta; Li Lin
Journal:  PLoS One       Date:  2016-09-21       Impact factor: 3.240

10.  Mouse Specific Cleavage-Resistant RAGE Splice Variant.

Authors:  Tohru Fukai
Journal:  PLoS One       Date:  2016-09-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.